Cost utility analysis of end stage renal disease treatment in Ministry of Health dialysis centres, Malaysia: Hemodialysis versus continuous ambulatory peritoneal dialysis.

OBJECTIVES:In Malaysia, there is exponential growth of patients on dialysis. Dialysis treatment consumes a considerable portion of healthcare expenditure. Comparative assessment of their cost effectiveness can assist in providing a rational basis for preference of dialysis modalities. METHODS:A cost...

Full description

Bibliographic Details
Main Authors: Naren Kumar Surendra, Mohd Rizal Abdul Manaf, Lai Seong Hooi, Sunita Bavanandan, Fariz Safhan Mohamad Nor, Shahnaz Shah Firdaus Khan, Ong Loke Meng, Abdul Halim Abdul Gafor
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0218422
id doaj-bb6988e630de4dbbbb9385d59aab44fe
record_format Article
spelling doaj-bb6988e630de4dbbbb9385d59aab44fe2021-03-03T21:06:00ZengPublic Library of Science (PLoS)PLoS ONE1932-62032019-01-011410e021842210.1371/journal.pone.0218422Cost utility analysis of end stage renal disease treatment in Ministry of Health dialysis centres, Malaysia: Hemodialysis versus continuous ambulatory peritoneal dialysis.Naren Kumar SurendraMohd Rizal Abdul ManafLai Seong HooiSunita BavanandanFariz Safhan Mohamad NorShahnaz Shah Firdaus KhanOng Loke MengAbdul Halim Abdul GaforOBJECTIVES:In Malaysia, there is exponential growth of patients on dialysis. Dialysis treatment consumes a considerable portion of healthcare expenditure. Comparative assessment of their cost effectiveness can assist in providing a rational basis for preference of dialysis modalities. METHODS:A cost utility study of hemodialysis (HD) and continuous ambulatory peritoneal dialysis (CAPD) was conducted from a Ministry of Health (MOH) perspective. A Markov model was also developed to investigate the cost effectiveness of increasing uptake of incident CAPD to 55% and 60% versus current practice of 40% CAPD in a five-year temporal horizon. A scenario with 30% CAPD was also measured. The costs and utilities were sourced from published data which were collected as part of this study. The transitional probabilities and survival estimates were obtained from the Malaysia Dialysis and Transplant Registry (MDTR). The outcome measures were cost per life year (LY), cost per quality adjusted LY (QALY) and incremental cost effectiveness ratio (ICER) for the Markov model. Sensitivity analyses were performed. RESULTS:LYs saved for HD was 4.15 years and 3.70 years for CAPD. QALYs saved for HD was 3.544 years and 3.348 for CAPD. Cost per LY saved was RM39,791 for HD and RM37,576 for CAPD. The cost per QALY gained was RM46,595 for HD and RM41,527 for CAPD. The Markov model showed commencement of CAPD in 50% of ESRD patients as initial dialysis modality was very cost-effective versus current practice of 40% within MOH. Reduction in CAPD use was associated with higher costs and a small devaluation in QALYs. CONCLUSIONS:These findings suggest provision of both modalities is fiscally feasible; increasing CAPD as initial dialysis modality would be more cost-effective.https://doi.org/10.1371/journal.pone.0218422
collection DOAJ
language English
format Article
sources DOAJ
author Naren Kumar Surendra
Mohd Rizal Abdul Manaf
Lai Seong Hooi
Sunita Bavanandan
Fariz Safhan Mohamad Nor
Shahnaz Shah Firdaus Khan
Ong Loke Meng
Abdul Halim Abdul Gafor
spellingShingle Naren Kumar Surendra
Mohd Rizal Abdul Manaf
Lai Seong Hooi
Sunita Bavanandan
Fariz Safhan Mohamad Nor
Shahnaz Shah Firdaus Khan
Ong Loke Meng
Abdul Halim Abdul Gafor
Cost utility analysis of end stage renal disease treatment in Ministry of Health dialysis centres, Malaysia: Hemodialysis versus continuous ambulatory peritoneal dialysis.
PLoS ONE
author_facet Naren Kumar Surendra
Mohd Rizal Abdul Manaf
Lai Seong Hooi
Sunita Bavanandan
Fariz Safhan Mohamad Nor
Shahnaz Shah Firdaus Khan
Ong Loke Meng
Abdul Halim Abdul Gafor
author_sort Naren Kumar Surendra
title Cost utility analysis of end stage renal disease treatment in Ministry of Health dialysis centres, Malaysia: Hemodialysis versus continuous ambulatory peritoneal dialysis.
title_short Cost utility analysis of end stage renal disease treatment in Ministry of Health dialysis centres, Malaysia: Hemodialysis versus continuous ambulatory peritoneal dialysis.
title_full Cost utility analysis of end stage renal disease treatment in Ministry of Health dialysis centres, Malaysia: Hemodialysis versus continuous ambulatory peritoneal dialysis.
title_fullStr Cost utility analysis of end stage renal disease treatment in Ministry of Health dialysis centres, Malaysia: Hemodialysis versus continuous ambulatory peritoneal dialysis.
title_full_unstemmed Cost utility analysis of end stage renal disease treatment in Ministry of Health dialysis centres, Malaysia: Hemodialysis versus continuous ambulatory peritoneal dialysis.
title_sort cost utility analysis of end stage renal disease treatment in ministry of health dialysis centres, malaysia: hemodialysis versus continuous ambulatory peritoneal dialysis.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2019-01-01
description OBJECTIVES:In Malaysia, there is exponential growth of patients on dialysis. Dialysis treatment consumes a considerable portion of healthcare expenditure. Comparative assessment of their cost effectiveness can assist in providing a rational basis for preference of dialysis modalities. METHODS:A cost utility study of hemodialysis (HD) and continuous ambulatory peritoneal dialysis (CAPD) was conducted from a Ministry of Health (MOH) perspective. A Markov model was also developed to investigate the cost effectiveness of increasing uptake of incident CAPD to 55% and 60% versus current practice of 40% CAPD in a five-year temporal horizon. A scenario with 30% CAPD was also measured. The costs and utilities were sourced from published data which were collected as part of this study. The transitional probabilities and survival estimates were obtained from the Malaysia Dialysis and Transplant Registry (MDTR). The outcome measures were cost per life year (LY), cost per quality adjusted LY (QALY) and incremental cost effectiveness ratio (ICER) for the Markov model. Sensitivity analyses were performed. RESULTS:LYs saved for HD was 4.15 years and 3.70 years for CAPD. QALYs saved for HD was 3.544 years and 3.348 for CAPD. Cost per LY saved was RM39,791 for HD and RM37,576 for CAPD. The cost per QALY gained was RM46,595 for HD and RM41,527 for CAPD. The Markov model showed commencement of CAPD in 50% of ESRD patients as initial dialysis modality was very cost-effective versus current practice of 40% within MOH. Reduction in CAPD use was associated with higher costs and a small devaluation in QALYs. CONCLUSIONS:These findings suggest provision of both modalities is fiscally feasible; increasing CAPD as initial dialysis modality would be more cost-effective.
url https://doi.org/10.1371/journal.pone.0218422
work_keys_str_mv AT narenkumarsurendra costutilityanalysisofendstagerenaldiseasetreatmentinministryofhealthdialysiscentresmalaysiahemodialysisversuscontinuousambulatoryperitonealdialysis
AT mohdrizalabdulmanaf costutilityanalysisofendstagerenaldiseasetreatmentinministryofhealthdialysiscentresmalaysiahemodialysisversuscontinuousambulatoryperitonealdialysis
AT laiseonghooi costutilityanalysisofendstagerenaldiseasetreatmentinministryofhealthdialysiscentresmalaysiahemodialysisversuscontinuousambulatoryperitonealdialysis
AT sunitabavanandan costutilityanalysisofendstagerenaldiseasetreatmentinministryofhealthdialysiscentresmalaysiahemodialysisversuscontinuousambulatoryperitonealdialysis
AT farizsafhanmohamadnor costutilityanalysisofendstagerenaldiseasetreatmentinministryofhealthdialysiscentresmalaysiahemodialysisversuscontinuousambulatoryperitonealdialysis
AT shahnazshahfirdauskhan costutilityanalysisofendstagerenaldiseasetreatmentinministryofhealthdialysiscentresmalaysiahemodialysisversuscontinuousambulatoryperitonealdialysis
AT onglokemeng costutilityanalysisofendstagerenaldiseasetreatmentinministryofhealthdialysiscentresmalaysiahemodialysisversuscontinuousambulatoryperitonealdialysis
AT abdulhalimabdulgafor costutilityanalysisofendstagerenaldiseasetreatmentinministryofhealthdialysiscentresmalaysiahemodialysisversuscontinuousambulatoryperitonealdialysis
_version_ 1714818795486314496